Cost impact of complications in meningococcal disease: evidence from a United States managed care population.

@article{Davis2011CostIO,
  title={Cost impact of complications in meningococcal disease: evidence from a United States managed care population.},
  author={Keith L. Davis and Derek A Misurski and Jacqueline Miller and Sudeep J Karve},
  journal={Human vaccines},
  year={2011},
  volume={7 4},
  pages={458-65}
}
OBJECTIVES To compare health care utilization and associated costs among patients with and without invasive meningococcal disease (IMD)-related sequelae. METHODS A retrospective analysis of an administrative claims database from 1998-2009 was performed. Patients with an IMD-related inpatient admission and continuous health plan enrollment selected and categorized by presence (complicated-IMD) or absence (uncomplicated-IMD) IMD-related sequelae during the follow-up year. Differences in the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2010
View 1 Excerpt

Epidemiological profile of meningococcal disease in the United States.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2010
View 3 Excerpts

Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…